A New Treatment Option for Heavy Menstrual Bleeding

• Status: Unknown status
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Women with measured menstrual bleeding >80ml per cycle and no contraindications to combined oral contraceptive use will be assigned to an oestradiol/nomegestrol acetate oral contraceptive for 3 cycles during which they will collect all menstrual blood and send all used sanitary protection to the laboratory at the University of Sydney for estimation of blood loss by the alkaline haematin method.

Hypothesis:

An estradiol/nomogestrel acetate (E2/NOMAC) combined pill will be effective in controlling HMB in the majority of women without structural pelvic pathology.

Main outcome:

The primary efficacy end-point will be the proportion of women with a reduction of menstrual blood loss ≥ 50% from baseline.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sydney Centre for Reproductive Health Research
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Contraceptive Agents; Contraceptives, Oral

Criteria

Inclusion Criteria:

• Women aged 18-50 years having regular menstrual cycles

• Women willing to collect all sanitary protection for 6 cycles

• Women with no contraindications to use of combined hormonal contraception

• Women not using any hormonal contraception or any treatment for HMB

• Women who have no demonstrable uterine pathology on pelvic ultrasound

• Women who have demonstrated a menstrual blood loss (MBL) >80mls in 2 of 3 menstrual periods during the pre-treatment phase will be eligible to enter the treatment phase

Exclusion Criteria:

• Women for whom combined oral contraceptives are contraindicated

• Women unwilling to collect all sanitary protection for 6 cycles

• Women using hormonal contraception or any treatment for HMB

• Women who have demonstrable uterine pathology on pelvic ultrasound

• Women who have demonstrated a MBL ≤80mls in 2 of 3 consecutive menstrual periods